Secura Bio® Media

News and Events

FEB 09, 2022, 6:00 AM ET

Secura Bio Announces Final Patient Enrolled in the COPIKTRA® (duvelisib) (PRIMO) Study in Relapsed and Refractory Peripheral T-cell Lymphoma

View Press Release »

DEC 14, 2021, 9:00 AM ET

Secura Bio Announces the Presentation of New COPIKTRA® (duvelisib) Data for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas (PTCL)

View Press Release »

DEC 03, 2021, 4:30 PM ET

Secura Bio Announces COPIKTRA® (duvelisib) Strategic Focus On T-cell Lymphoma And Voluntary U.S. Withdrawal Of The Relapsed Or Refractory Follicular Lymphoma Indication

View Press Release »

NOV 30, 2021, 4:45 PM ET

Secura Bio Announces U.S. Withdrawal of FARYDAK® (panobinostat) NDA

View Press Release »

SEP 22, 2021, 9:00 AM ET

Secura Bio Announces European Distribution Agreement for COPIKTRA® with Clinigen Healthcare Limited

View Press Release »

JUN 09, 2021, 9:00 AM ET

COPIKTRA® (duvelisib) Receives European Union Marketing Authorization for the Treatment of Relapsed or Refractory CLL and Refractory FL

View Press Release »

FEB 02, 2021, 9:00 AM ET

Secura Bio Announces New Data Regarding the Combination of FARYDAK® (panobinostat) with Subcutaneous Bortezomib and Dexamethasone

View Press Release »

AUG 10, 2020, 9:23 AM ET

Secura Bio Signs Agreement to Acquire Global Rights to Oncology Drug Copiktra®

View Press Release »

Mar 05, 2019, 10:07 AM ET

Secura Bio Announces $145 Million Financing Led By Athyrium Capital Management

View Press Release »